Regional Data Variability Challenges Summit's Lung Cancer Drug and Keytruda Rival
TL;DR Summary
Summit Therapeutics' lung cancer drug ivonescimab showed promising overall survival and progression-free survival results in a Phase 3 trial, but regional differences, especially between Western and Chinese patients, have raised concerns about its competitive potential against Merck's Keytruda, leading to a decline in the company's stock.
- Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences Yahoo Finance
- Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster statnews.com
- Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend Fierce Pharma
- WCLC25: Summit's Keytruda challenger faces more questions over regional data differences FirstWord Pharma
- Akeso Drops Most in 3 Months on Mixed Drug Data From US Partner Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
88%
399 → 46 words
Want the full story? Read the original article
Read on Yahoo Finance